Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progressive and symmetric erythrokeratoderma.

David H Chu1, Martha P Arroyo

  • 1Ronald O. Perelman Department of Dermatology, New York University, USA.

Dermatology Online Journal
|November 5, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks.

American journal of clinical dermatology·2025
Same author

Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III Trials.

Dermatology and therapy·2025
Same author

Early Evidence of Safety, Clinical Benefit, and Pharmacokinetics of Roflumilast Cream 0.3% Once Daily for Treatment of Mild or Moderate Plaque Psoriasis in Children Aged 2-11 Years.

Pediatric dermatology·2025
Same author

Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial.

JAMA dermatology·2025
Same author

Patient and healthcare provider perspectives on treatment patterns and patient satisfaction of seborrheic dermatitis in the United States.

The Journal of dermatological treatment·2025
Same author

Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial.

Pediatric dermatology·2025
Same journal

Pellagra associated with iron deficiency.

Dermatology online journal·2026
Same journal

Demodicosis: A frequently underrecognized cause of recalcitrant ear pruritus.

Dermatology online journal·2026
Same journal

Association of alopecia areata with COVID-19 vaccination: A vaccine adverse events reporting system analysis.

Dermatology online journal·2026
Same journal

Gender based price differences in 5% minoxidil foam: The impact of generic alternatives and bulk packaging.

Dermatology online journal·2026
Same journal

Retrospective analysis of filler complications reported in the manufacturer and user facility device experience database from 2015 to 2025.

Dermatology online journal·2026
Same journal

Characterizing barriers to care in patients with hidradenitis suppurativa.

Dermatology online journal·2026
See all related articles

This case study highlights a 9-year-old boy with progressive erythrokeratoderma. Research suggests loricrin may be a candidate gene for this rare skin disorder.

Area of Science:

  • Dermatology
  • Human Genetics

Background:

  • Erythrokeratoderma is a group of rare autosomal genodermatoses characterized by progressive, symmetric, and diffuse hyperkeratosis of the skin.
  • The specific genetic basis for many forms of erythrokeratoderma remains elusive, hindering targeted therapeutic approaches.

Observation:

  • A 9-year-old boy presented with a progressive and symmetric erythrokeratoderma.
  • Clinical examination revealed diffuse hyperkeratosis consistent with the disorder.

Findings:

  • The study reviews clinical features associated with erythrokeratoderma.
  • Evidence is presented supporting loricrin (LOR) as a potential candidate gene for this genodermatosis.

Implications:

  • Identifying candidate genes like loricrin is crucial for understanding the molecular pathogenesis of erythrokeratoderma.

Related Experiment Videos

  • Further research into loricrin's role could pave the way for improved diagnostics and potential gene-targeted therapies for patients with erythrokeratoderma.